BIOHIT Healthcare is distributing test kits for the diagnosis of both current and past COVID-19 infections to help in the fight against coronavirus in the UK. The new product line includes the MutaPLEX® Coronavirus kit from Immundiagnostik AG (IDK) – a real-time RT-PCR assay to screen for infected individuals – and Epitope Diagnostics Inc’s (EDI’s) immunodiagnostic tests for IgM and IgG COVID-19 antibodies, to detect past infections.
The IDK MutaPLEX coronavirus screening assay allows the detection of SARS-CoV-2 viral RNA in a variety of biological specimens, especially nasal/throat swabs. This real time RT-PCR kit contains all the reagents, primers and dual-labelled probes required for the amplification and simultaneous differentiation of RNA from SARS-CoV-2 and other betacoronaviruses, as well as house-keeping genes designed to prevent false negative results due to insufficient sample collection or transport problems.
EDI’s Novel Coronavirus COVID-19 ELISA kits provide qualitative detection of antibodies in patient serum, indicating a past COVID-19 infection. The IgM assay provides the earliest immunodiagnostic indication of an infection, while the IgG test can be used to aid detection and provide an indication of long-term immunological response, making it particularly useful in cases where clustering is suspected or differential diagnosis is required.
These tests extend and complement BIOHIT’s repertoire of diagnostic kits for gastroenterology, aiding the evaluation of patients with both GI and upper respiratory complaints, as COVID-19 may include stomach and bowel symptoms in some cases. Inflammatory bowel disease patients being treated with immunosuppressive agents should also be considered at high risk for COVID-19, making differential diagnosis essential.
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:31:372021-01-08 11:07:51BIOHIT supplies COVID-19 detection kits in the UK
BioCity, a life science incubator and business collective has released its biennial publication, the UK Life Science Start-Up Report, an in-depth analysis of emerging businesses within the life sciences across the UK.
The report looks at the prevalence of life science start-ups in the UK over the past five years and the broader landscape in which they operate to also asses the quality of UK life science start-ups.
The report documents an unprecedented period of growth for the life sciences, thanks in part to a change in the funding landscape, expressed in a four-fold increase to £2.8 billion of investment in early-stage ventures, compared to the previous five-year period.
Multiple factors are highlighted as driving this expansion, but of greatest impact was Industry news January 2020 11 | the emergence of a number of significant venture funds able and willing to make very large investments in early stage businesses. Also identified as a contributing factor is the increasing use of smaller companies and academia as sources of innovation by large pharma companies aiming to counteract falling R&D productivity. Simultaneously, many universities such as Bristol, Newcastle and Aberdeen introduced a gear change in spin-out formation.
Author of the report, Dr Glenn Crocker said: “Both the number of companies starting up and the amount invested in them has taken off. We have seen a 50% increase in the number of companies and a four-fold increase in investment going into them; this will likely result in a substantial increase in the demand for space. We estimate that this cohort of businesses alone could require 1.4 million sq ft of specialist facilities over the next five years. One consequence of this demand growth is that real estate investors are being increasingly attracted to the sector.”
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:31:372021-01-08 11:07:58Life science start-up report reveals boom in new life science ventures
Olympus’ Image of the Year Award recognizes the best in life science imaging worldwide. Participants can win a CX43 microscope with a DP27 digital camera, X Line objectives, or an OM-D E-M5 Mark II camera. Those interested in participating can enter until 31 January 2020 by uploading images at www.olympus-lifescience.com/ioty. Winners will be selected by a jury panel and announced in March 2020. The jury consists of global representatives from both science and the arts, including photo- grapher Ron Caplain; Geoff Williams, a bioimaging facility manager at Brown University; Urs Ziegler, the head of a microscopy imaging facility at the University of Zurich; Stefan Terjung, the operational manager of an advanced light microscopy facility at EMBL Heidelberg; Hiroaki Misono, a graduate school professor of brain science at Doshisha University; Zhu Xueliang, a professor at the Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences; Yalin Wang, Director of Biomedical Research Core Facilities at Westlake University, Hangzhou, China; and Wendy Salmon, a light microscopy specialist of a bioimaging facility at MIT. All entries will be evaluated based on artistic and visual aspects, scientific impact, and microscope proficiency. Regional prizes in Asia, Europe, and the Americas will be awarded in addition to the global prize. The Image of the Year European Life Science Light Microscopy Award began in 2017 to celebrate both the artistic and scientific value of microscopy images. Now on a global scale, the competition aims to encourage people to look at scientific images in a new way, appreciate their beauty, and share images with others. Participants may upload up to three microscopy images when submitting the online form. Images, accompanied by a brief explanation that notes the equipment used, can be uploaded until 31 January 2020. The jury will select and notify the winners in March 2020.
www.olympus-lifescience.com/ioty
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:31:372021-01-08 11:08:08Olympus launches the first Global Image of the Year Award
The ReactoMate DATUM from Asynt is a high quality, dual-rod stainless steel and aluminium support system built to ensure the stability and safety of your lab reactor. Sturdy, yet compact, the ReactoMate DATUM support system can accommodate a wide range of reaction vessels from 100 mL up to 5000 mL.
Designed with user-friendliness in mind, the ReactoMate DATUM support system incorporates a suite of innovative features.
Changing a vessel supported by the ReactoMate DATUM is as simple as “Clip & Click”. The novel neck clamp allows fast changeover between reactor vessel sizes thereby enabling simple reaction scale-up, whilst the ingenious mounting mechanism ensures excellent stability and alignment every time.
The Reactomate DATUM support system is fully compatible with all leading brands of overhead stirrers and circulator heating/cooling systems. Designed by chemists for chemists, low-friction polymer bearings line both the overhead stirrer alignment chuck and the neck support to ensure smooth and easy operation.
Ideally suited for use within a benchtop fume hood, adjustable feet allow you to level the ReactoMate DATUM support system ensuring stability and security while you work. Each DATUM system is also supplied with a moulded drip tray that fits perfectly within the base of the support, for safely catching any drips and spills from the reaction vessel during draining.
With a wide range of accessories and upgrades available, including drain manifolds and automation packages, the ReactoMate DATUM support system is the perfect all-rounder for laboratory scale reactions.
For more information, visit: www.asynt.com/product/reactomate-datum
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:31:372021-01-08 11:07:46ReactoMate DATUM — a user-friendly support system for laboratory scale reactions
As the COVID-19 pandemic progresses in countries around the globe, there is an urgent need for rapid and reliable point-of-need detection testing. Dolomite Microfluidics and Mologic are working together to accelerate the development and launch of these tests.
UK-based Mologic is a leading developer of rapid response diagnostic tests for diseases such as malaria and Ebola virus disease. Clients include the Bill & Melinda Gates Foundation, where Mologic is leveraging its core technology through its Centre for Advanced Rapid Diagnostics (CARD) to develop the next generation of ultra-sensitive point-of-care diagnostics which are easy to use andinexpensive to manufacture – critical to the success of many global health programmes. Most recently, Mologic has received UK Government funding to develop and manufacture a high sensitivity test for COVID-19 that generates results within minutes – rather than hours or days – without the need for a laboratory or specialist equipment.
The technology behind these tests involves the use of precisely manufactured nanoparticles. Dolomite specialises in equipment that allows the development and scale-up of precision nanoparticles. This is achieved by using microfluidic technology to retain advanced control of production conditions. Dolomite is working with Mologic to combine ground-breaking diagnostic technology with continuous flow microfluidic manufacturing processes to accelerate the validation and release of Mologic’s COVID-19 diagnostic test.
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:31:372021-01-08 11:07:54Dolomite and Mologic collaborate to scale-up manufacture of nanoparticles for Covid-19 diagnostic tests
GAMBICA is the Trade Association for Instrumentation, Control, Automation and Laboratory Technology in the UK. Our insight and influence help our members to be more competitive by increasing their knowledge and impact. Together we remove barriers and maximise the market potential in our industry. GAMBICA members are active in the following sectors: • Industrial automation products and systems • Process instrumentation and control • Laboratory technology • Test and measurement equipment for electrical and electronics industries
www.gambica.org.uk
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:31:372021-01-08 11:08:01GAMBICA at Medica
A City of Hope scientist and his colleagues have developed a user-friendly approach to creating “theranostics” – therapy combined with diagnostics – that target specific tumours and diseases.
Key to the process are molecules called metallocorroles, which serve as versatile platforms for the development of drugs and imaging agents. City of Hope’s John Termini, Ph.D., and his colleagues at the California Institute of Technology and the Israel Institute of Technology developed a novel method to prepare cell-penetrating nanoparticles called “metallocorrole/protein nanoparticles.” The theranostics could both survive longer in the body and better snipe disease targets.
The study details a unique way the researchers prepared the theranostics that may be generalizable to many similar molecules.
“Through collaborative brainpower, we were able to create something that has huge chemotherapeutic potential,” Termini said. “Down the road, theranostics such as this could shorten treatment duration and diminish the dreaded side effects so many cancer patients fear.”
City of Hope
https://tinyurl.com/y67c26em
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:31:372021-01-08 11:08:11Creating more potent cancer therapy using ‘theranostics’
by Dr Tolga Durak Around the world, organizations are building next-generation research facilities intended to encourage communication, collaboration and creativity. However, these new spaces must overcome a wide range of complex challenges to meet the needs of researchers today and in the future. This article explores five important questions that should be considered in order to build an innovation space that is safe, successful and productive.
Fundamental questions for good design
Research facility design and construction is evolving rapidly, as organizations around the world strive to create work environments that meet the needs of today’s scientists. Whether these new spaces are relatively small-scale makerspaces, large pharmaceutical manufacturing plants, or tightly regulated high-containment laboratories, they are being built to foster communication, collaboration, and innovation, often in ways that depart significantly from the traditional R&D rubric. As a result, every stage of the process – from initial site assessment, architectural design, and construction and continuing all the way through to ongoing maintenance and operation – must be approached with fresh eyes. To get started, design and construction teams must consider the following five fundamental questions. 1. Who is going to work in the facility and what will they need to be successful? Most research projects now span multiple disciplines, and laboratory spaces often need to accommodate the varied needs of biologists, chemists, engineers, physicists and/or others – all working together but with different methods. Research facility design must accommodate each specialty’s unique requirements across a wide spectrum that includes equipment, infrastructure (electrical, ventilation, etc), information technology (IT), workflow and compliance. In addition, designers must factor in flexibility, so workspaces can adapt as the research advances and needs change. 2. What is required for compliance? Navigating regulatory boards and obtaining approvals can be a complex, time-consuming, and expensive process, especially for clinical research facilities. Typically, these structures must be constructed in compliance with Good Laboratory Practice (GLP) regulations, Good Manufacturing Practice (GMP) regulations, and other guidelines and mandates from local, state and federal jurisdictions. In addition, laboratories that research or use infectious agents or other biological hazards must comply with regulations based on the degree of the health-related risk associated with the work being conducted. The four biosafety levels (BSLs) of containment – BSL-1, BSL-2, BSL-3, and BSL-4 – aim to safeguard against the accidental release of pathogenic organisms and other biohazards and may involve airflow systems, containment rooms, sealed container storage, waste management, decontamination procedures, and security capabilities. Clearly, the challenges of compliance need to be tackled early in the design process because meeting all of the requirements can take years, which increases the risk that research priorities change and/or that key staff moves on to other projects. 3. How sustainably can we build it? When people think about sustainable research facility design, they usually focus on power and water consumption. Granted, researchers typically use lots of heat-generating equipment (which then require complementary cooling solutions). Their labs also generally need extensive ventilation, sophisticated sensor networks, uninterrupted power supplies – as well as back-up redundancies for all of these systems. However, in a broader sense, sustainable research facility design also addresses the health and well-being of the workforce. That means air quality, natural light, workflow and productivity considerations, material selection, and all related aesthetics can drive design and construction processes as well. 4. How will the needs of this facility change? Science is constantly evolving, and research priorities will shift over time. Likewise, technology, regulations and workforce needs will change too. Flexibility and adaptability need to be key considerations of every plan, and designers and developers have to strike a balance between short- and long-term needs. In some cases, permanent or portable modular components may be the most efficient and cost-effective options. 5. Is building the best business decision? For some organizations, the best business decision may be to share laboratory space, rather than to build their own. Entering into a partnership, collaboration or lease agreement with an organization that is already operating a facility can expedite research results, reduce costs, ease the burden of meeting compliance requirements and even stimulate innovation. Of course, benefits like those must be weighed against potential disadvantages, such as the lack of customization, loss of control and the risks associated with failure to protect intellectual property.
Summary
Thoughtful consideration of these five key questions will help you create an innovation space that will meet your research needs today and for years to come. As you work through your answers to each one, be sure to solicit input from architects, engineers, builders and others who have the experience and expertise to guide you in the process. Adopting a team approach is essential to building a next-generation innovation space that is that is safe, successful and productive. The author Tolga Durak PhD Environment, Health and Safety Office, Professional Education, MIT, Cambridge, MA 02139, USA E-mail: tdurak@mit.edu
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:31:372021-01-08 11:07:49Enabling innovation: designing research facilities
Cardiac troponin is the gold standard biomarker for diagnosis of acute myocardial infarction. The introduction of high-sensitive cardiac troponin assays has further strengthened its power in early rule-in/rule-out testing. However, since these assays are susceptible to hemolysis interference, sample rejection due to hemolysis (commonly seen in samples from the Emergency Department) remains one of the biggest challenges.
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:31:372021-01-08 11:07:56High-sensitive cardiac troponin T: the issue of hemolysis interference
A new blood test in development has shown ability to screen for numerous types of cancer with a high degree of accuracy, a trial of the test shows.
The test, developed by GRAIL, Inc., uses next-generation sequencing technology to probe DNA for tiny chemical tags (methy-lation) that influence whether genes are active or inactive. When applied to nearly 3,600 blood samples – some from patients with cancer, some from people who had not been diagnosed with cancer at the time of the blood draw – the test successfully picked up a cancer signal from the cancer patient samples, and correctly identified the tissue from where the cancer began (the tissue of origin). The test’s specificity – its ability to return a positive result only when cancer is actually present – was high, as was its ability to pinpoint the organ or tissue of origin, researchers found.
The new test looks for DNA, which cancer cells shed into the bloodstream when they die. In contrast to “liquid biopsies,” which detect genetic mutations or other cancer-related alterations in DNA, the technology focuses on modifications to DNA known as methyl groups. Methyl groups are chemical units that can be attached to DNA, in a process called methylation, to control which genes are “on” and which are “off.” Abnormal patterns of methylation turn out to be, in many cases, more indicative of cancer – and cancer type – than mutations are. The new test zeroes in on portions of the genome where abnormal methylation patterns are found in cancer cells.
“Our previous work indicated that methylation-based assays outperform traditional DNA-sequencing approaches to detecting multiple forms of cancer in blood samples,” said the study’s lead author, Geoffrey Oxnard, MD, of Dana-Farber. “The results of the new study demonstrate that such assays are a feasible way of screening people for cancer.”
In the study, investigators analysed cell-free DNA (DNA that had once been confined to cells but had entered the bloodstream upon the cells’ death) in 3,583 blood samples, including 1,530 from patients diagnosed with cancer and 2,053 from people without cancer. The patient samples comprised more than 20 types of cancer, including hormone receptor-negative breast, colorectal, esophageal, gallbladder, gastric, head and neck, lung, lymphoid leukemia, multiple myeloma, ovarian, and pancreatic cancer.
The overall specificity was 99.4%, meaning only 0.6% of the results incorrectly indicated that cancer was present. The sensitivity of the assay for detecting a pre-specified high mortality cancers (the percent of blood samples from these patients that tested positive for cancer) was 76%. Within this group, the sensitivity was 32% for patients with stage I cancer; 76% for those with stage II; 85% for stage III; and 93% for stage IV. Sensitivity across all cancer types was 55%, with similar increases in detection by stage. For the 97% of samples that returned a tissue of origin result, the test correctly identified the organ or tissue of origin in 89% of cases.
Detecting even a modest percent of common cancers early could translate into many patients who may be able to receive more effective treatment if the test were in wide use, Oxnard remarked.
Dana-Farber Cancer Institutewww.dana-farber.org/newsroom/news-releases/2019/new-blood-test-capable-of-detecting-multiple-types-of-cancer/
https://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png003wmediahttps://clinlabint.com/wp-content/uploads/sites/2/2020/06/clinlab-logo.png3wmedia2020-08-26 09:31:372021-01-08 11:08:04New blood test capable of detecting multiple types of cancer
We may ask you to place cookies on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience and to customise your relationship with our website.
Click on the different sections for more information. You can also change some of your preferences. Please note that blocking some types of cookies may affect your experience on our websites and the services we can provide.
Essential Website Cookies
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to provide the website, refusing them will affect the functioning of our site. You can always block or delete cookies by changing your browser settings and block all cookies on this website forcibly. But this will always ask you to accept/refuse cookies when you visit our site again.
We fully respect if you want to refuse cookies, but to avoid asking you each time again to kindly allow us to store a cookie for that purpose. You are always free to unsubscribe or other cookies to get a better experience. If you refuse cookies, we will delete all cookies set in our domain.
We provide you with a list of cookies stored on your computer in our domain, so that you can check what we have stored. For security reasons, we cannot display or modify cookies from other domains. You can check these in your browser's security settings.
.
Google Analytics Cookies
These cookies collect information that is used in aggregate form to help us understand how our website is used or how effective our marketing campaigns are, or to help us customise our website and application for you to improve your experience.
If you do not want us to track your visit to our site, you can disable this in your browser here:
.
Other external services
We also use various external services such as Google Webfonts, Google Maps and external video providers. Since these providers may collect personal data such as your IP address, you can block them here. Please note that this may significantly reduce the functionality and appearance of our site. Changes will only be effective once you reload the page
Google Webfont Settings:
Google Maps Settings:
Google reCaptcha settings:
Vimeo and Youtube videos embedding:
.
Privacy Beleid
U kunt meer lezen over onze cookies en privacy-instellingen op onze Privacybeleid-pagina.